Designation could ac­cel­er­ate CLR 131 devel­op­ment and underscores the need for new treat­ments

Florham Park, NJ (Press Release) – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, to­day an­nounced that the U.S. Food and Drug Admin­istra­tion (FDA) has granted Fast Track Desig­na­tion for CLR 131 in fourth line or later re­lapsed / re­frac­tory mul­ti­ple myeloma. CLR 131 is the com­pany’s small-molecule radiotherapeutic phos­pho­lipid drug con­ju­gate (PDC™) de­signed to de­liver cytotoxic radi­a­tion directly and sel­ectively to cancer cells and cancer stem cells. It is cur­rently being eval­u­ated in Cellectar’s on­go­ing CLOVER-1 …

Median over­all sur­vival of 22.0 months observed in Cohorts 1-4

Florham Park, NJ (Press Release) – Cellectar Biosciences (Nasdaq: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, to­day an­nounced median over­all sur­vival (mOS) in Cohorts 1-4 of the com­pany’s on­go­ing Phase 1 clin­i­cal trial eval­u­ating CLR 131 for the treat­ment of re­lapsed / re­frac­tory (R/R) mul­ti­ple myeloma (MM). The results showed mOS of 22.0 months among 15 patients, all of whom were heavily pre­treated, averaging five prior lines of sys­temic ther­apy. Each patient in Cohorts 1-4 of this dose-escalation study re­ceived a …

Patent covers composition of mat­ter and use in solid and liquid tumor cancer indi­ca­tions

Florham Park, NJ (Press Release) – Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of targeted treat­ments for cancer, an­nounces that the Japan Patent Office has granted the pat­ent titled “Phos­pho­lipid Analogs as Diapeutic Agents and Methods of Use Thereof” with appli­ca­tion num­ber 2016135920. The pat­ent provides composition of mat­ter and use pro­tec­tion for the com­pany’s pro­pri­e­tary phos­pho­lipid ether (PLE) analogs and spe­cif­i­cally CLR 131 in breast, brain, leukemias and a variety of other cancers.

“Certain cancers such as pedi­atric lym­phomas and leukemias have a …

Clinical Trials to Advance Across Multiple He­ma­tol­ogy Programs

Florham Park, NJ (Press Release) – Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, an­nounces to­day that the U.S. Food and Drug Admin­istra­tion (FDA) has granted an exemption to the Import Alert placed on the Centre for Probe De­vel­op­ment and Com­mer­cial­i­za­tion (CPDC), the sole supplier of the CLR 131. The exemption for CLR 131 is ef­fec­tive im­medi­ately for all he­ma­tol­ogy stud­ies and, in re­sponse, Cellectar is preparing to dose patients in the sec­ond frac­tion­ated dose cohort of the …

Madison, WI (Press Release) – Cellectar Biosciences (Nasdaq: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, to­day up­dates interim over­all sur­vival (OS) data from the com­pany’s on­go­ing Phase 1b clin­i­cal trial eval­u­ating CLR 131 for the treat­ment of re­lapsed/refractory (R/R) mul­ti­ple myeloma (MM).

The results to date show that OS is cur­rently at 19.4 months. Cellectar con­tinues to monitor these patients and in­tends to up­date OS results as data be­come avail­able. All 15 patients from the Phase 1b, single-dose cohorts were …

Madison, WI (Press Release) – Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, an­nounces to­day that the U.S. Food and Drug Admin­istra­tion (FDA) has ini­ti­ated direct talks with the com­pany con­cern­ing a possible exemption for CLR 131 from the Import Alert placed on the Centre for Probe Develop­ment and Com­mer­cial­i­za­tion (CPDC), the sole supplier of Cellectar’s drug CLR 131.

As an­nounced on August 10, 2018, Cellectar was in­formed by CPDC of the Import Alert on August 7, 2018, …

Madison, WI (Press Release) – Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of targeted treat­ments for can­cer, an­nounces that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. P150207US03, entitled “Alkylphosphocholine analogs for mul­ti­ple myeloma imaging and ther­apy.” The claims in this pat­ent cover a method of use for CLR 131, the com­pany's pro­pri­e­tary lead Phospholipid Drug Conjugate™ (PDC™) in mul­ti­ple myeloma (MM). Cellectar and the Wisconsin Alumni Research Foundation (WARF) are joint owners of the pat­ent and Cellectar has licensed …